IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

IDEXX LABORATORIES INC /DE

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$555.80−4.56 (-0.81%)

Close on Oct 19, 2026

Market cap: $44.08B
P/E (TTM): 39.1
Dividend yield: –

IDEXX LABORATORIES INC /DE income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	4,304	3,898	3,661	3,367	3,215	2,707	2,407	2,213	1,969	1,775	1,602	1,486	1,377	1,293	1,219	1,103	1,032	1,024
Cost of Revenue	1,644	1,519	1,471	1,363	1,326	1,136	1,041	972	872	800	712	670	621	594	572	525	505	494
Gross Profit	2,660	2,379	2,190	2,004	1,889	1,571	1,366	1,242	1,097	975	890	816	756	699	647	579	526	530
Research & Development	251	220	191	255	161	141	133	118	109	101	100	98	88	82	76	69	65	71
Selling, General & Admin	1,048	1,031	902	851	796	735	680	632	575	524	482	458	401	355	334	306	285	287
Selling & Marketing	644	589	566	525	487	434	418	387	354	317	300	284	243	217	205	180	168	170
General & Administrative	405	442	336	326	310	301	261	245	221	207	183	174	158	138	129	127	117	117
Advertising Expenses	4.00	3.40	4.20	5.00	3.30	1.40	1.50	1.80	1.70	2.10	1.20	1.20	1.50	1.10	1.20	1.70	1.10	–
Operating Expenses	1,300	1,251	1,093	1,106	–	–	–	750	–	–	–	–	–	–	–	–	–	–
Operating Income	1,360	1,128	1,097	899	932	695	553	491	413	350	300	260	267	263	236	204	176	172
Interest Expense	39	31	42	40	30	33	31	35	37	32	29	15	5.39	3.85	3.55	2.42	1.92	4.59
Asset Impairment Charges	–	0.25	1.48	2.35	5.15	2.50	0.97	0	0	0	0	0	0	0	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	–	–	-0.17	-3.50	-0.62	-1.60	-2.47	-0.84
Pretax Income	1,324	1,110	1,061	860	903	662	522	458	381	322	273	247	263	261	234	202	175	170
Income Tax Expense	265	222	216	181	158	80	94	81	118	100	81	65	75	82	73	61	52	54
Net Income incl. Noncontrolling Interests	–	–	845	679	745	582	428	377	263	222	192	182	188	178	162	141	122	116
Minority Interest in Earnings	–	–	0	0	0.00	0.36	0.07	0.02	0.13	0.01	0.06	0.05	-0.01	0.02	-0.03	0.04	0.01	–
Net Income	1,059	888	845	679	745	582	428	377	263	222	192	182	188	178	162	141	122	116
EPS (Basic)(per share)	13.17	10.77	10.17	8.12	8.74	6.82	4.97	4.34	3.00	2.47	2.07	1.82	1.77	1.62	1.43	1.23	1.04	0.97
EPS (Diluted)(per share)	13.08	10.67	10.06	8.03	8.60	6.71	4.89	4.26	2.94	2.44	2.05	1.79	1.74	1.59	1.39	1.19	1.01	0.94
Shares Outstanding (Basic, Weighted)(shares)	80	82	83	84	85	85	86	87	88	90	93	100	106	110	114	115	118	120
Shares Outstanding (Diluted, Weighted)(shares)	81	83	84	85	87	87	88	88	90	91	94	102	108	112	116	119	121	124
EBITDA	1,505	1,258	1,212	1,011	1,037	791	641	575	496	428	369	319	321	315	284	250	226	220
Provision for Credit Losses	8.43	6.87	5.55	5.83	1.48	4.95	0.66	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 62.4%
Operating margin: 32.0%
Net margin: 25.0%
Return on equity, FY2025: 66.2%

Financial strength

Current ratio: 1.17
Debt to equity: 0.28
Debt to assets: 13.1%
Cash to current liabilities: 15.3%

Valuation

P/E ratio: 39.1
Price to sales: 9.68
Price to book: 27.34
Dividend yield: –